Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
HCCPrecision Therapy
Interventions
DRUG

HAIC + Tislelizumab +lenvatinib

"All patients were treated with HAIC combined with tislelizumab and lenvatinib.~1. HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.~2. Lenvatinib was started before HAIC treatment, discontinued during HAIC treatment, Oral 8 mg or 12mg once a day depending body weight.~3. First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later."

Trial Locations (1)

Unknown

RECRUITING

Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Chen Xiaoping

OTHER